Fig. 1: ANXA2 is upregulated in cisplatin-induced AKI mice. | Cell Death Discovery

Fig. 1: ANXA2 is upregulated in cisplatin-induced AKI mice.

From: Annexin A2 plays a key role in protecting against cisplatin-induced AKI through β-catenin/TFEB pathway

Fig. 1

A Quantitative data shows the relative expression of different ANXA family members in cisplatin-treated mice or control mice. *P < 0.05, **P < 0.01, ***P < 0.001 versus Ctrl group (n = 5). B, C Western blot analysis shows the expression of ANXA2 in two groups. ***P < 0.001 versus Ctrl (n = 5). D Immunofluorescence staining demonstrates the expression of ANXA2 is upregulated across different sections in AKI-affected kidney. White arrows indicate positive staining. Scale bars, 75 μm (low magnification); 25 μm (high magnification). E–G Quantification of positive staining. **P < 0.01, ***P < 0.001 versus Ctrl group (n = 5). H Co-localization of ANXA2 (red) with LTL (green, a marker for proximal renal tubule), PNA (green, a marker for distal renal tubule) and DBA (green, a marker for collecting duct) are shown. Results show ANXA2 is largely expressed in proximal and distal tubules, but localizes in collecting ducts to a less extent. White arrows indicate positive staining. Scale bars, 25 μm. I, J Western blotting shows urinary ANXA2 expression. Mouse urine samples were collected and tested by western blotting. The urinary ANXA2 expression was quantified by normalizing to Urinary creatinine. ***P < 0.001 versus Ctrl (n = 5). Abbreviations: ANXA2 Annexin A2, Ctrl control.

Back to article page